Vertex Pharmaceuticals (VRTX) Insider Trading & Ownership $479.79 +5.29 (+1.11%) Closing price 02/28/2025 04:00 PM EasternExtended Trading$477.78 -2.02 (-0.42%) As of 02/28/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Vertex Pharmaceuticals (NASDAQ:VRTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage0.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)9Amount OfInsider Selling(Last 12 Months)$29.34 M Get VRTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Vertex Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address VRTX Insider Buying and Selling by Quarter Vertex Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/27/2025Ourania TatsisEVPSell530$475.34$251,930.20 2/18/2025Ourania TatsisEVPSell244$455.06$111,034.64 2/11/2025Ourania TatsisEVPSell310$459.83$142,547.30 11/15/2024David AltshulerEVPSell15$478.56$7,178.40 8/30/2024Jeffrey M LeidenChairmanSell3,784$499.00$1,888,216.00 8/30/2024Sangeeta N BhatiaDirectorSell646$500.00$323,000.00 8/7/2024Carmen BozicCMOSell2,280$476.75$1,086,990.00 8/1/2024Bruce I SachsDirectorSell5,295$508.00$2,689,860.00 7/24/2024Carmen BozicCMOSell2,280$488.46$1,113,688.80 7/22/2024Reshma KewalramaniCEOSell15,202$497.00$7,555,394.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 7/10/2024Carmen BozicCMOSell2,280$487.34$1,111,135.20 6/26/2024Carmen BozicCMOSell2,280$471.72$1,075,521.60 6/12/2024Carmen BozicCMOSell2,280$478.00$1,089,840.00 6/12/2024Edward Morrow Atkinson IIIEVPSell7,288$478.00$3,483,664.00 5/30/2024Ourania TatsisEVPSell2,350$439.11$1,031,908.50 5/29/2024Carmen BozicCMOSell2,280$445.56$1,015,876.80 5/28/2024Charles F Wagner JrCFOSell3,250$454.79$1,478,067.50 5/24/2024Reshma KewalramaniCEOSell1,565$457.00$715,205.00 5/22/2024Bruce I SachsDirectorSell7,073$448.00$3,168,704.00 (Data available from 1/1/2013 forward) VRTX Insider Trading Activity - Frequently Asked Questions Who is on Vertex Pharmaceuticals's Insider Roster? The list of insiders at Vertex Pharmaceuticals includes Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Carmen Bozic, Charles F Wagner Jr, David Altshuler, Edward Morrow Atkinson III, Jeffrey M Leiden, Jonathan Biller, Joy Liu, Kristen Ambrose, Lloyd Carney, Margaret G Mcglynn, Ourania Tatsis, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, and Yuchun Lee. Learn more on insiders at VRTX. What percentage of Vertex Pharmaceuticals stock is owned by insiders? 0.20% of Vertex Pharmaceuticals stock is owned by insiders. Learn more on VRTX's insider holdings. Which Vertex Pharmaceuticals insiders have been selling company stock? The following insiders have sold VRTX shares in the last 24 months: Amit Sachdev ($1,354,013.28), Bastiano Sanna ($5,176,395.04), Bruce I Sachs ($21,162,600.50), Carmen Bozic ($14,548,270.35), Charles F Wagner Jr ($3,998,815.80), David Altshuler ($28,945.53), Edward Morrow Atkinson III ($3,483,664.00), Jeffrey M Leiden ($13,592,878.66), Jonathan Biller ($211,523.60), Kristen Ambrose ($672,727.74), Ourania Tatsis ($2,777,597.64), Reshma Kewalramani ($12,174,267.36), Sangeeta N Bhatia ($786,860.82), and Stuart A Arbuckle ($4,834,423.04). How much insider selling is happening at Vertex Pharmaceuticals? Insiders have sold a total of 216,931 Vertex Pharmaceuticals shares in the last 24 months for a total of $84,802,983.36 sold. Which members of congress are trading Vertex Pharmaceuticals? Tommy Tuberville (R-AL) has sold shares of Vertex Pharmaceuticals in the last year totaling $8,000. Vertex Pharmaceuticals Key ExecutivesDr. Jeffrey Marc Leiden M.D. (Age 68)Ph.D., Executive Chairman Compensation: $95.02kDr. Reshma Kewalramani FASN (Age 51)M.D., CEO, President & Director Compensation: $5.59MMr. Charles F. Wagner Jr. (Age 56)Executive VP & CFO Compensation: $2.12MMr. Stuart A. Arbuckle B.Sc. (Age 58)Executive VP & COO Compensation: $2.76MDr. David M. Altshuler M.D. (Age 59)Ph.D., Executive VP & Chief Scientific Officer Compensation: $2.17MMs. Kristen C. Ambrose CPA (Age 47)Senior VP & Chief Accounting Officer Mr. Mike TirozziSVP and Chief Information & Data OfficerSusie LisaSenior Vice President of Investor RelationsMr. Jonathan Biller J.D. (Age 60)Executive VP & Chief Legal Officer Ms. Nina DevlinSenior VP & Chief Communications Officer More Insider Trading Tools from MarketBeat Related Companies Amgen Insider Selling Gilead Sciences Insider Selling Regeneron Pharmaceuticals Insider Selling Alnylam Pharmaceuticals Insider Selling Biogen Insider Selling United Therapeutics Insider Selling Incyte Insider Selling BioMarin Pharmaceutical Insider Selling Neurocrine Biosciences Insider Selling Exelixis Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:VRTX) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored3 Undervalued Stocks to Get Today (Revealed)These 3 Stocks Should Do Well Even in a Recession If you’re looking for stocks that offer significant upsid...StockEarnings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
